Omeros (NASDAQ:OMER) Earns Buy Rating from D. Boral Capital

Omeros (NASDAQ:OMER – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at D. Boral Capital in a research note issued on Friday,Benzinga reports. They currently have a $36.00 price target on the biopharmaceutical company’s stock. D. Boral Capital’s target price indicates a potential upside of 295.60% from the company’s current price. […]

Leave a Reply

Your email address will not be published.

Previous post AptarGroup, Inc. (NYSE:ATR) Shares Purchased by HighTower Advisors LLC
Next post HighTower Advisors LLC Cuts Stock Holdings in Citizens Financial Group, Inc. (NYSE:CFG)